Atorvastatin treatment in Systemic Lupus Erythematosus patients
Completed
- Conditions
- Systemic lupus erythematosusMusculoskeletal Diseases
- Registration Number
- ISRCTN51612701
- Lead Sponsor
- Polish Ministry of Science and Higher Education (Poland)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1. Patients aged 20 - 73, either sex
2. Fulfilled at least 4 American College of Rheumatology (ACR) classification criteria for SLE
3. In stable clinical conditions (no need for immunosuppressive therapy intensification, i.e. current immunosuppressive drug dose increase or introduction of an additional immunosuppressive drug within last 3 months)
Exclusion Criteria
1. Known cancer
2. Clinical symptoms of coronary heart disease or heart failure (New York Heart Association [NYHA] III or IV class)
3. Renal failure (creatinine clearance less than 30 ml/min)
4. Respiratory failure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measured at 0 and 12 months:<br>1. Calcium deposits in coronary arteries<br>2. Number of myocardial left ventricle segments with perfusion defects
- Secondary Outcome Measures
Name Time Method Measured at 0, 3, 6, 12 months:<br>1. Symptoms of myocardial ischaemia<br>2. Need for reperfusion therapy<br>3. Deaths